Cargando…

Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence

PURPOSE OF REVIEW: We summarize the best evidence for statins in the prevention and treatment of heart failure. RECENT FINDINGS: In patients with cardiovascular risk factors or established atherosclerotic cardiovascular disease (but without heart failure), statins reduce the risk of incident heart f...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Matthew M. Y., Sattar, Naveed, McMurray, John J. V., Packard, Chris J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660504/
https://www.ncbi.nlm.nih.gov/pubmed/31350612
http://dx.doi.org/10.1007/s11883-019-0800-z
_version_ 1783439312699785216
author Lee, Matthew M. Y.
Sattar, Naveed
McMurray, John J. V.
Packard, Chris J.
author_facet Lee, Matthew M. Y.
Sattar, Naveed
McMurray, John J. V.
Packard, Chris J.
author_sort Lee, Matthew M. Y.
collection PubMed
description PURPOSE OF REVIEW: We summarize the best evidence for statins in the prevention and treatment of heart failure. RECENT FINDINGS: In patients with cardiovascular risk factors or established atherosclerotic cardiovascular disease (but without heart failure), statins reduce the risk of incident heart failure—mainly by preventing myocardial infarction although an additional benefit from reducing myocardial ischemia cannot be excluded. However, in patients with established heart failure, statins do not reduce the risk of cardiovascular death, which is mainly caused by pump failure and ventricular arrhythmias. Retrospective analyses, however, suggest that statins may reduce the rate of heart failure hospitalization and atherosclerotic events (which are proportionately much less common in these patients than heart failure hospitalization or death). SUMMARY: Statin therapy should probably be continued in patients with coronary artery disease developing heart failure, although the weak evidence and small benefit may not justify the use of this treatment in very elderly patients with a short life expectancy and in which polypharmacy is a problem.
format Online
Article
Text
id pubmed-6660504
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-66605042019-08-07 Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence Lee, Matthew M. Y. Sattar, Naveed McMurray, John J. V. Packard, Chris J. Curr Atheroscler Rep Statin Drugs (M. Tikkanen, Section Editor) PURPOSE OF REVIEW: We summarize the best evidence for statins in the prevention and treatment of heart failure. RECENT FINDINGS: In patients with cardiovascular risk factors or established atherosclerotic cardiovascular disease (but without heart failure), statins reduce the risk of incident heart failure—mainly by preventing myocardial infarction although an additional benefit from reducing myocardial ischemia cannot be excluded. However, in patients with established heart failure, statins do not reduce the risk of cardiovascular death, which is mainly caused by pump failure and ventricular arrhythmias. Retrospective analyses, however, suggest that statins may reduce the rate of heart failure hospitalization and atherosclerotic events (which are proportionately much less common in these patients than heart failure hospitalization or death). SUMMARY: Statin therapy should probably be continued in patients with coronary artery disease developing heart failure, although the weak evidence and small benefit may not justify the use of this treatment in very elderly patients with a short life expectancy and in which polypharmacy is a problem. Springer US 2019-07-27 2019 /pmc/articles/PMC6660504/ /pubmed/31350612 http://dx.doi.org/10.1007/s11883-019-0800-z Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Statin Drugs (M. Tikkanen, Section Editor)
Lee, Matthew M. Y.
Sattar, Naveed
McMurray, John J. V.
Packard, Chris J.
Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
title Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
title_full Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
title_fullStr Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
title_full_unstemmed Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
title_short Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
title_sort statins in the prevention and treatment of heart failure: a review of the evidence
topic Statin Drugs (M. Tikkanen, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660504/
https://www.ncbi.nlm.nih.gov/pubmed/31350612
http://dx.doi.org/10.1007/s11883-019-0800-z
work_keys_str_mv AT leematthewmy statinsinthepreventionandtreatmentofheartfailureareviewoftheevidence
AT sattarnaveed statinsinthepreventionandtreatmentofheartfailureareviewoftheevidence
AT mcmurrayjohnjv statinsinthepreventionandtreatmentofheartfailureareviewoftheevidence
AT packardchrisj statinsinthepreventionandtreatmentofheartfailureareviewoftheevidence